At the 2016 Society of Nuclear Medicine and Molecular Imaging Annual Meeting, researchers presented the results of a genetic blood test called NETest®, which measures the specific NET genes circulating in the blood that are believed to predict responsiveness to peptide receptor radionuclide therapy
In a panel moderated by Daniel C Malone, PhD, RPh, International Society for Pharmacoeconomics and Outcomes Research president and professor of pharmacy at the University of Arizona (Tuscon, AZ), members of two prominent pharmacy benefit managers (PBMs) and a large-scale health care insurance company discussed the advantages and challenges of using real-world evidence in payer decision making. For more ISPOR coverage, click here.
Developers of some of the key value frameworks in the industry gathered to discuss how these resources are changing health care.
At ISPOR 2016, health care professionals, policy makers, and payer representatives gathered to discussed developments in outcomes research and value-based care.
Patients with chronic lymphocytic leukemia (CLL) who are relapsed or refractory (R/R) to ibrutinib or idelalisib may benefit from venetoclax.
Investigators assessed how response rate changed when patients were treated with different doses of brigatinib.
Researchers conducted a study to generate estimates of costs associated with breast cancer adjuvant chemotherapy regimens.
Researchers developed a model to estimate the cost per month of survival in patients treated with daratumumab, carfilzomib, and pomalidomide plus dexamethasone.